Cmc hematology

Cmc hematology DEFAULT

If you or a loved one is living with a blood disorder, getting the right care is essential to your well-being. At Atrium Health Levine Cancer Institute (LCI), we offer expert diagnosis and treatment of a wide range of non-cancerous (benign) blood conditions.

Our Center for Bleeding Disorders and Anemia, located on LCI’s main campus in Charlotte, is among the most trusted care centers for benign blood disorders in the Southeast. With deep clinical experience and expertise in the latest therapies, our team of specialists can help you manage your condition and enhance your quality of life.

Blood disorders we treat

Levine Cancer Institute is home to top hematologists who specialize in all types of benign blood and bone marrow diseases. Some of the most common conditions we treat include:

  • Anemia, including iron deficiency anemia and sickle cell anemia
  • Bleeding disorders, including hemophilia and von Willebrand disease
  • Clotting disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE) and factor V Leiden
  • Platelet disorders, including thrombocytopenia (low platelets) and ITP

Our experts also provide treatment for other rare and complex diseases. If you need care for a blood condition not listed here, please call 980-442-4363 to find a doctor who can help you.

Do you need blood cancer treatment?

Levine Cancer Institute offers world-class care for all cancers of the blood and bone marrow, including:

Treatment options

Your specific care path depends on your unique condition. Even with the same diagnosis, every person’s needs are different. That’s why it’s critical that your treatment is truly tailored to you.

We offer the latest therapies for the full spectrum of blood disorders, and our specialists have the expertise to create a comprehensive care plan that’s customized just for you. Your treatment may include any of the following:

  • Blood transfusion, where donated blood is provided to you through a thin tube placed in a vein in your arm. We offer simple transfusions and exchange transfusions.
  • Replacement therapy, where we regularly infuse your blood with missing proteins – or “clotting factors” – so that it can clot.
  • Anticoagulant medicines (blood thinners), which can reduce the risk of developing blood clots.
  • Medicines for sickle cell disease, including hydroxyurea and L-glutamine, that can help reduce the number of pain crises and hospitalizations.
  • Bone marrow transplant, also known as stem cell transplant, which replaces diseased cells with healthy blood stem cells. We offer the latest approaches, including autologous (self), full-match and half-matched transplants, at the region’s only comprehensive transplant and cellular therapy center.

Clinical trials for blood disorders

Clinical trials give you more opportunities to find the best treatment for you. As a leader in hematology research, our extensive clinical trials program gives you access to the most innovative treatments before they’re widely available.

Our program includes trials for non-cancerous blood disorders, and we work hard to connect every interested and eligible patient with a clinical trial that may be effective for their specific condition.

Our Providers

For more information or to schedule an appointment with a hematologist, please call 980-442-4363.

For referring physicians

When you refer a patient to Levine Cancer Institute, you can be sure they’ll benefit from comprehensive, coordinated care that’s tailored to their unique needs. We’ll work hand in hand with you to determine the best treatment strategy and keep you involved throughout the patient journey.

To refer a patient to a hematologist at Levine Cancer Institute, please call 980-442-4363.

Sours: https://atriumhealth.org/medical-services/specialty-care/cancer-care/hematology-oncology-blood-disorders

Hematology

The department currently sees 1200 new outpatients every year and admits about 700 patients every year for inpatient care. These patients come from all over India and cover the whole spectrum of blood diseases. Acute lymphatic leukemia is being treated with the German BFM protocols with 70% long term survival in children. The departments sees over 60 new patients with severe aplastic anemia each year and provides consultation haematology services for the hospital.

The department started its BMT program in 1986 and has done 165 transplants until August 1997, and is currently doing 30 allogeneic bone marrow transplants a year with a three bed positive pressure HEPA filtered transplant unit. Thalassemia is one of the main indications and 60 transplants have been done so far with a success rate of 75% even though most of the patients are in Class II or III. Bone marrow transplants are also done for patients with acute leukemia, aplastic anemia, chronic myeloid leukemia and myelodysplasia. Autologous transplants are being performed mainly for patients with multiple myeloma using mobilized peripheral blood stem cells.

Comprehensive care is available for patients with hemophilia. Major surgery is also being performed for these patients in the institution with coagulation factors received as gifts .This service is being utilized by patients with crippling deformities who are being effectively rehabilitated in association with the orthopedic and rehabilitation teams in the institution. Efficacy and safety of low dose factor replacement for post operative hemostasis is being evaluated.

The department is now able to confirm the mutation in most patients and carriers with thalassemia by reverse dot blot and DGGE techniques. The department is also able to provide antenatal diagnosis at 8-10 weeks for couples who are carriers for thalassemia. The department is working on providing this service for patients with hemophilia and Glanzman’s thrombasthenia.

The department is currently an Advanced Center of the Indian Council of Medical Research for Bone Marrow Transplantation in Thalassemia and on this project is working on the pharmacokinetics of Busulphan in patients with thalassemia. The department is also working on DNA fingerprinting techniques for the assessment of chimerism following bone marrow transplantation. Other research interests include the following:

  • Evaluation of genetic interactions that lead to thalassemia intermedia.
  • Clinical and genetic evaluation of Glanzman’s thrombasthenia.
  • Genetics of hemophilia in India.
  • Genetics of thrombophilia in India.
Sours: https://www.cmch-vellore.edu/sites/research/Hematology.html
  1. Mickey mouse papa
  2. Alan kay alone
  3. Milwaukee sds core bits
  4. Neca 18 inch figures

Conway Medical Center is making giant strides toward enhancing its cancer care program through a new affiliation and the upcoming opening of a new state-of-the art cancer center inside the hospital.

The CMC Cancer Center will include infusion services for patients in need of chemotherapy, intravenous medications and other blood products. Equipped to offer all of the latest technologies in a single convenient location, CMC’s Cancer Center provides blood and platelet transfusions, blood draws, hydration therapy, injections, as well as traditional intravenous chemotherapy infusions.  The space features a peaceful and relaxing atmosphere for patients who may be receiving treatment at the center frequently for many hours at a time.

To assist with the expansion of CMC’s oncology services, the medical center has become a Duke Cancer Network Affiliate providing CMC access to the clinical experience and expertise of the Duke Cancer Institute. This relationship gives CMC access to the most current training and staff education when it comes to cancer and cancer-related health issues. CMC will also have access to Duke University Health System’s best practices and clinical trials in Oncology.

As the relationship progresses, CMC’s goal is to further enhance its service offerings to allow patients to receive care locally, close to family and friends.  CMC’s access to Duke Health System resources will be invaluable in maintaining and expanding upon the excellent quality of care the medical center provides to Horry County and the surrounding areas.

CMC has also invested in bringing a specialty trained oncologist to our community. Heading up the infusion center at CMC is Dr. Najla Itani who specializes in Oncology, Hematology and Internal Medicine.  Inspired by a strong desire to serve the oncology patient population in a community setting, Dr. Itani is passionate about connecting with people and getting to know the real person behind the disease.  “I strongly believe that building a strong physician-patient connection that is founded in trust is at the core of excellent patient care. I want my patients to feel that we are an extension of their family and will care for them in both the best and worst of times.”

Dr. Itani’s drive to make a difference in the lives of her patients and to work in underserved areas makes her a perfect addition to the CMC Cancer Center.  “My patients will always come first and I will do my best to provide the best care possible for each patient no matter how difficult that may be.”

CLICK HERE to learn more about cancer care at CMC and what to expect when receiving treatments.

Sours: https://www.conwaymedicalcenter.com/locations/cmc-cancer-center/
My visit to CMC Vellore. (Hematology)
hwang-jimmy
Jimmy Hwang, MD, FACP
Program Director

Dr. Hwang is the Director of the Hematology/Medical Oncology fellowship at the LCI, and the Chief of the GI Medical Oncology section, since joining the Carolinas Healthcare System Levine Cancer Institute in September of 2013. He received his medical degree from the University of Pittsburgh School of Medicine, and completed his hematology/medical oncology fellowship at the University of Pittsburgh Cancer Institute. He was a member of the faculty at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center from 2001 to 2013. He served as the Program Director of the Fellowship Program in Hematology/Medical Oncology from 2006 to 2013. Dr. Hwang is a Clinical Associate Professor of the University of North Carolina at Chapel Hill, School of Medicine.

Carrizosa-Daniel
Daniel Carrizosa, MD
Associate Program Director

Dr. Carrizosa is one of the Associate Program Directors in the Hematology/Medical Oncology fellowship at the LCI. He received his medical degree at the University of North Carolina, Chapel Hill School of Medicine, and completed his hematology/medical oncology fellowship at the University of North Carolina Memorial Hospital. He has active research interests in thoracic malignancies and health care disparities.

Fisher-Julie
Julie Fisher, MD
Associate Program Director

Dr. Fisher is one of the Associate Program Directors in the Hematology/Medical Oncology fellowship at the LCI. She received her medical degree from the Medical University of South Carolina, and completed her fellowship I hematology/medical oncology at the Columbia University Medical Center. Her areas of interest focus on breast cancer.

 
Asim Amin, MD, PhD
Key Clinical Faculty

Dr. Amin is the co-director of the Immunotherapy program at LCI. He received his medical degree from the King Edward Medical College in Lahore, Pakistan, and a PhD in immunology from the University of California, Davis. He completed his fellowship in hematology/medical oncology at the Georgetown University Medical Hospital Lombardi Cancer Center. He was subsequently a member of the faculty at the Lombardi Cancer Center. He has been widely published in melanoma, renal cell cancer and immunotherapy.

Copelan-Edward
Edward Copelan, MD, FACP
Key Clinical Faculty

Dr. Copelan is the Chair of the Department of Hematologic Oncology and Blood Disorders at the Levine Cancer Institute. He received his medical degree from Tufts University School of Medicine, and completed his fellowship in hematology and medical oncology at the Ohio State University Hospitals, with an additional fellowship in bone marrow transplantation from the University of California Los Angeles. He has been on the faculty and director of bone marrow transplantation at the Ohio State University and then Cleveland Clinic, also becoming the director of the Leukemia program at the latter.

 
Ometayo Fasan, MBBS, MRCP
Key Clinical Faculty

Dr. Fasan is the Director of apheresis at LCI. He received his medical degree from the University of Lagos, and completed his Hematology/Oncology fellowship at Temple University Hospital, and then joined the faculty at the Temple University Hospital and Fox Chase Cancer Center. He is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill. His research interests include lymphomas and leukemias.

Gerber-Jonathan
Jonathan Gerber, MD
Key Clinical Faculty

Dr. Gerber is the Director of the Leukemia section at LCI. He received his medical degree and completed his fellowship in Hematology from the Johns Hopkins School of Medicine, and subsequently joined the faculty at Johns Hopkins. He is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

ghosh-nilanjan
Nilanjan Ghosh, MD, PhD
Key Clinical Faculty

Dr. Gerber is the Director of the Leukemia section at LCI. He received his medical degree and completed his fellowship in Hematology from the Johns Hopkins School of Medicine, and subsequently joined the faculty at Johns Hopkins. He is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

grunwald-michael
Michael Grunwald, MD
Key Clinical Faculty

Dr. Grunwald received his medical degree from the Johns Hopkins School of Medicine, and completed his hematology/medical oncology fellowship at Johns Hopkins. Dr. Grunwald is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill. He is extensively published in acute myeloid leukemia.

Knovich_MaryAnn_web
Mary Ann Knovich, MD
Key Clinical Faculty

Dr. Knovich is the Director of Bleeding Disorders at LCI. She received her medical degree from the Pennsylvania State University College of Medicine. She completed her fellowship in Hematology/Medical Oncology at the Wake Forest University Baptist Medical Center, and then joined the faculty there, rising to the rank of Associate Professor, and was the Medical Director of the Comprehensive Hemophilia Diagnostic and Treatment Center, Adult Sickle Cell Program, and Apheresis Unit, before joining LCI. She has given many lectures, and been extensively published in iron disorders, sickle cell and non-malignant hematologic diseases.

Miller-David-W
David Miller, MD
Key Clinical Faculty

Dr. Miller is the Director of Non-malignant hematology at LCI, and is the Chairman of the Center of Excellence for Thrombosis and Hemostasis; of the Blood and Tissue Committee and of the Blood Conservation committee of the Atrium Health. He received his medical degree from the Medical College of Georgia, and completed his fellowship in Hematology and Oncology from the Duke University Medical Center.

Sumrall-Ashley
Ashley Sumrall, MD
Key Clinical Faculty

Dr. Sumrall received her medical degree from the University of Mississippi Medical Center. She completed her Hematology/Medical Oncology fellowship at the University of Mississippi Medical Center, then an additional Neuro-Oncology Fellowship at the Duke University Medical Center. She has been extensively published on central nervous system malignancies. She is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

Tan-Antoinette
Antoinette Tan, MD, M.H.Sc.
Key Clinical Faculty

Dr. Tan is the Chief of Breast Medical Oncology, and Co-Director of the Phase I program at LCI. She received her medical degree from the Robert Wood Johnson Medical School. She completed her Oncology fellowship at the National Cancer Institute, then joined the faculty at the Rutgers Cancer Institute of New Jersey, and has been the Chair of the American Society of Clinical Oncology Cancer Education Committee.

Usmani-Saad
Saad Usmani, MD, FACP
Key Clinical Faculty

Dr. Usmani is the Director of Plasma Cell Disorders at LCI and the Director of Clinical Research in Hematologic Malignancies at LCI. He received his medical degree from Allama Iqbal Medical College. He completed his Hematology and Medical Oncology Fellowship at the University of Connecticut, then joined the faculty of the University of Arkansas. He is a Clinical Associate Professor of Medicine at the University of North Carolina, Chapel Hill.

Sours: https://atriumhealth.org/education/graduate-medical-education/physician-fellowships/internal-medicine/hematology-oncology

Hematology cmc

Practices & Facilities


logo

Practices & Facilities

Oncology/Hematology

Providers
Practices & Facilities
  • Timothy Bael, MD

    Timothy Bael, MD

    Specialty: Oncology/Hematology

    Medical school: University of Pittsburgh School of Medicine (Pittsburgh, PA)

    Residency: Columbia-Presbyterian Medical Center (New York, NY) Internal Medicine

    Fellowship: Duke University Medical Center (Durham, NC) Hematology & Oncology

    Phone: 607-272-5414

  • Charles Garbo, MD

    Charles Garbo, MD

    Specialty: Oncology/Hematology

    Medical school: University of Vermont Robert Larner College of Medicine (Burlington, VT)

    Residency: Saint Vincent Hospital (Worcester, MA) Internal Medicine

    Fellowship: University of Massachusetts Medical School (Worcester, MA) Hematology & Oncology

    Phone: 607-272-5414

  • Julie Specht, MD

    Julie Specht, MD

    Specialty: Oncology/Hematology

    Medical school: SUNY Downstate College of Medicine (Brooklyn, NY)

    Residency: Columbia University Medical Center (New York, NY) Internal Medicine

    Fellowship: Columbia University Medical Center (New York, NY) Hematology & Oncology

    Phone: 607-272-5414

CHP medical practices provide professional service in many speciality areas

Questions? We'd love to speak with you.

Sours: https://cayugahealthpartners.com/search/result/speciality/19
What is Haematology? - Dr. Rajib De (Bengali)

.

You will also be interested:

.



337 338 339 340 341